Home > Newsletters > Drug Industry Daily > Lucentis Appears Primed to Be First Sanctioned Treatment for Diabetic Macular Edema
Drug Industry Daily
July 26, 2012 | Vol. 11 No. 146
Lucentis Appears Primed to Be First Sanctioned Treatment for Diabetic Macular Edema
While flagging some safety issues, an FDA staff report on two pivotal Phase III trials of Genetech’s Lucentis in patients with significant diabetic macular edema appears to clear a path for the drug’s approval for that condition — currently with no agency-sanctioned treatment option.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.